AI Article Synopsis
- The study evaluated the effectiveness of a chemotherapy combination of docetaxel (DTX), estramustine phosphate (EMP), and hydrocortisone in treating hormone-refractory prostate cancer (HRPC) in 63 patients.
- More than half of the patients experienced a significant reduction in prostate-specific antigen (PSA) levels, with median overall survival reported at 14 months.
- While the treatment led to high instances of severe side effects, it was generally considered safe and beneficial, prompting further research to identify which patients may benefit the most.
Article Abstract
Objective: To assess the combination of docetaxel (DTX), estramustine phosphate (EMP) and hydrocortisone for patients with hormone-refractory prostate cancer (HRPC).
Methods: A total of 63 patients with HRPC were treated with a chemotherapeutic regimen including DTX, EMP, and hydrocortisone. Clinical and pathological features were correlated to serum prostate-specific antigen (PSA) recurrence and survival rates. Incidence and degree of toxicities were also retrospectively reviewed.
Results: A median of 11 courses of chemotherapy was administered per patient. PSA levels decreased by >50% in 32 (51%) patients and >90% in 18 (29%) patients. Median time to PSA progression was 6 months (range from 1 to 41 months) and median time of overall survival was 14 months (range from 1 to 56 months). In a univariate analysis to predict overall survival, PSA, hemoglobin, alkaliphosphatase, and performance status prior to the chemotherapy were significant factors. Despite grade 3-4 neutropenia in 87% of patients, grade 5 interstitial pneumonia in one patient and grade 4-5 myocardial infarction in two patients were recognized, the regimen seemed to be relatively safe.
Conclusions: Combination chemotherapy with DTX, EMP and hydrocortisone provides survival benefits for patients with HRPC with an acceptable toxicity profile. We need to further evaluate who might benefit most from this regimen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1442-2042.2010.02544.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients.
Int J Urol
July 2010
Department of Urology, Tokyo Medical University, Tokyo, Japan.
Article Synopsis
- The study evaluated the effectiveness of a chemotherapy combination of docetaxel (DTX), estramustine phosphate (EMP), and hydrocortisone in treating hormone-refractory prostate cancer (HRPC) in 63 patients.
- More than half of the patients experienced a significant reduction in prostate-specific antigen (PSA) levels, with median overall survival reported at 14 months.
- While the treatment led to high instances of severe side effects, it was generally considered safe and beneficial, prompting further research to identify which patients may benefit the most.
Role of angiotensin II in the pressor response to cortisol in fetal sheep during late gestation.
Exp Physiol
May 2004
Department of Physiology, University of Cambridge, Downing Street, Cambridge CB2 3EG, UK.
Glucocorticoids increase blood pressure in utero, but the mechanisms responsible are unclear. This study investigated the hypothesis that the hypertensive effects of cortisol depend upon a functional renin-angiotensin system (RAS). The study examined, in the sheep fetus, whether blockade of the Ang II type 1 (AT(1)) specific receptor prevented the cortisol-induced increase in blood pressure.
View Article and Find Full Text PDFTwenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients.
Endocr J
February 2002
Department of Endocrinology and Metabolism, Ankara University, Medical Faculty, Turkey.
The current study aimed to investigate the midterm (24 hour) response of 17-hydroxyprogesterone (17-OHP) and dehydroepiandrosterone sulphate (DHEA-S) to synthetic high-dose adrenocorticotropin (ACTH) in adrenal incidentalomas (Al). Seventeen patients with Al and 40 age- and sex-matched controls received synthetic ACTH (tetracosactide, 1000 microg, IM). Plasma, 17-OHP and DHEA-S were collected in basal conditions and after 1, 4, 6, 8 and 24 hours.
View Article and Find Full Text PDFPaclitaxel and docetaxel in prostate cancer.
Hematol Oncol Clin North Am
June 2001
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Although their ultimate value in prostate cancer therapy remains to be defined in randomized trials, docetaxel and paclitaxel are active agents in HRPC. Combination therapies using either of these taxanes plus oral EMP show reproducible antitumor activity that appears to be greater and more durable than that of single-agent treatment. Although the optimal combination and schedule have not been determined, weekly paclitaxel and EMP and docetaxel given every 3 weeks or by weekly infusion with EMP are useful treatment options for patients with progressive HRPC.
View Article and Find Full Text PDFDampening of the cortisol response to handling at 3 months in human infants and its relation to sleep, circadian cortisol activity, and behavioral distress.
Dev Psychobiol
December 1998
Institute of Child Development, University of Minnesota, Minneapolis 55455-0345, USA.
The decrease in responsiveness of the hypothalamic-pituitary-adrenocortical (HPA) system is marked over the first months of life. Seventy-eight healthy infants (44 girls), 7 to 15 weeks old, were given a laboratory mock physical examination. Salivary cortisol samples were collected pre- and postexamination and at home.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!